JP7805289B2 - 抗コネキシン抗体製剤 - Google Patents

抗コネキシン抗体製剤

Info

Publication number
JP7805289B2
JP7805289B2 JP2022520447A JP2022520447A JP7805289B2 JP 7805289 B2 JP7805289 B2 JP 7805289B2 JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022520447 A JP2022520447 A JP 2022520447A JP 7805289 B2 JP7805289 B2 JP 7805289B2
Authority
JP
Japan
Prior art keywords
antibody
formulation
pharmaceutical formulation
seq
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552152A (ja
JP2022552152A5 (https=
JPWO2021067775A5 (https=
Inventor
ヤンフェン ジャン，
Original Assignee
アラマブ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラマブ セラピューティクス， インコーポレイテッド filed Critical アラマブ セラピューティクス， インコーポレイテッド
Publication of JP2022552152A publication Critical patent/JP2022552152A/ja
Publication of JP2022552152A5 publication Critical patent/JP2022552152A5/ja
Publication of JPWO2021067775A5 publication Critical patent/JPWO2021067775A5/ja
Priority to JP2025010928A priority Critical patent/JP2025061811A/ja
Application granted granted Critical
Publication of JP7805289B2 publication Critical patent/JP7805289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022520447A 2019-10-02 2020-10-02 抗コネキシン抗体製剤 Active JP7805289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025010928A JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909267P 2019-10-02 2019-10-02
US62/909,267 2019-10-02
PCT/US2020/054036 WO2021067775A1 (en) 2019-10-02 2020-10-02 Anto-connexin antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025010928A Division JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Publications (4)

Publication Number Publication Date
JP2022552152A JP2022552152A (ja) 2022-12-15
JP2022552152A5 JP2022552152A5 (https=) 2023-10-10
JPWO2021067775A5 JPWO2021067775A5 (https=) 2023-10-10
JP7805289B2 true JP7805289B2 (ja) 2026-01-23

Family

ID=75273959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520447A Active JP7805289B2 (ja) 2019-10-02 2020-10-02 抗コネキシン抗体製剤
JP2025010928A Pending JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025010928A Pending JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Country Status (8)

Country Link
US (2) US12358981B2 (https=)
EP (1) EP4037703A4 (https=)
JP (2) JP7805289B2 (https=)
KR (1) KR20220113355A (https=)
CN (1) CN114786719A (https=)
AU (1) AU2020358101A1 (https=)
CA (1) CA3156812A1 (https=)
WO (1) WO2021067775A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN115825201B (zh) * 2022-07-28 2024-10-25 苏州凯劳生物科技有限公司 一种使用毛细管电泳仪电离还原蛋白二硫键并确定其自由巯基比例的方法
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187057A1 (en) 2017-04-06 2018-10-11 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP2019509283A (ja) 2016-02-26 2019-04-04 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
CN1981054A (zh) * 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
MX2010012324A (es) * 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
RU2408728C1 (ru) * 2009-07-28 2011-01-10 Федеральное государственное учреждение "Государственный Научный Центр Социальной и Судебной Психиатрии им. В.П. Сербского" (ФГУ "ГНЦССП Росздрава") Способ получения иммуногенного рекомбинантного экстраклеточного фрагмента коннексина-43
CA2806157C (en) 2010-07-26 2016-11-22 Les Laboratoires Servier Methods and compositions for liver cancer therapy
RU2457862C1 (ru) * 2011-07-07 2012-08-10 Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации Способ лечения низкодифференцированных глиом
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
IN2014MU01248A (https=) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3095897A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
US11427639B2 (en) * 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019509283A (ja) 2016-02-26 2019-04-04 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用
WO2018187057A1 (en) 2017-04-06 2018-10-11 Regeneron Pharmaceuticals, Inc. Stable antibody formulation

Also Published As

Publication number Publication date
CN114786719A (zh) 2022-07-22
AU2020358101A1 (en) 2022-04-28
JP2022552152A (ja) 2022-12-15
WO2021067775A1 (en) 2021-04-08
US20260049132A1 (en) 2026-02-19
EP4037703A1 (en) 2022-08-10
US20210101974A1 (en) 2021-04-08
KR20220113355A (ko) 2022-08-12
CA3156812A1 (en) 2021-04-08
US12358981B2 (en) 2025-07-15
EP4037703A4 (en) 2023-12-06
JP2025061811A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
JP7805289B2 (ja) 抗コネキシン抗体製剤
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
RU2339402C2 (ru) Лиофилизированный препарат, содержащий антитела против рецептора egf
KR102109053B1 (ko) 안정한 수성 항체 제제
US11912764B2 (en) Anti-connexin antibody formulations
CN113453719A (zh) 包含抗cd47抗体的制剂及其制备方法和用途
WO2020128792A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
JPWO2008029908A1 (ja) 抗体を含有する安定な凍結乾燥医薬製剤
TW202128133A (zh) 重組全人源抗ｔｉｇｉｔ單株抗體製劑及其製備方法和用途
HK40077586A (en) Anto-connexin antibody formulations
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies
HK1071306B (en) Lyophilised preparation comprising antibodies against the egf receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260113

R150 Certificate of patent or registration of utility model

Ref document number: 7805289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150